Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-02-14
2009-08-18
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07576065
ABSTRACT:
The present invention relates to a method of inducing neuronal production in a subject, a method of recruiting neurons to a subject's brain, and a method of treating a neurodegenerative condition by administering a neurotrophic factor and an inhibitor of pro-gliogenic bone morphogenetic proteins. Also disclosed is a method of suppressing astrocyte generation and inducing neuronal production in a subject, a method of treating a neurologic condition, and a method of suppressing glial scar formation in a subject by administering an inhibitor of pro-gliogenic bone morphogenetic proteins. Finally, the present invention involves a method of introducing a heterogeneous protein into a subject's brain and spinal cord by introducing a nucleic acid molecule encoding the heterogeneous protein introduced into the subject's ependyma, permitting the protein from the nucleic acid molecule to be expressed within the subject's ependyma, and permitting the expressed protein to migrate within the subject's brain and spinal cord.
REFERENCES:
patent: 5082670 (1992-01-01), Gage et al.
patent: 5196315 (1993-03-01), Ronnett et al.
patent: 5308763 (1994-05-01), Ronnett et al.
patent: 5453361 (1995-09-01), Yancopoulos et al.
patent: 5491084 (1996-02-01), Chalfie et al.
patent: 5654189 (1997-08-01), Lee et al.
patent: 5661032 (1997-08-01), Miller et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5753505 (1998-05-01), Luskin
patent: 5753506 (1998-05-01), Johe
patent: 5766948 (1998-06-01), Gage et al.
patent: 5770414 (1998-06-01), Gage et al.
patent: 5780300 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5830858 (1998-11-01), Rosenthal
patent: 5837535 (1998-11-01), Joseph et al.
patent: 5851832 (1998-12-01), Weiss et al.
patent: 5874304 (1999-02-01), Zolotukhin et al.
patent: 5958767 (1999-09-01), Snyder et al.
patent: 5968829 (1999-10-01), Carpenter
patent: 5980885 (1999-11-01), Weiss et al.
patent: 6000772 (1999-12-01), Miller et al.
patent: 6071889 (2000-06-01), Weiss et al.
patent: 6075007 (2000-06-01), Economides et al.
patent: 6225122 (2001-05-01), Sah et al.
patent: 6245564 (2001-06-01), Goldman et al.
patent: 6251669 (2001-06-01), Luskin
patent: 2001/0024827 (2001-09-01), Luskin
patent: WO 93/01275 (1993-01-01), None
patent: WO 94/02593 (1994-02-01), None
patent: WO 96/38541 (1996-05-01), None
patent: WO 96/38576 (1996-12-01), None
patent: WO 97/07200 (1997-02-01), None
patent: WO 98/32879 (1998-07-01), None
patent: WO 99/29279 (1999-06-01), None
patent: WO 99/49014 (1999-09-01), None
patent: WO 00/23571 (2000-04-01), None
patent: WO 01/46384 (2001-06-01), None
patent: WO 01/53503 (2001-07-01), None
Benraiss A. et al. 2001. Journal of Neuroscience 21:6718-6731.
Akaneya Y. et al. 1997. Journal of Neuroscience 17:6707-6716.
Lim DA, Noggin antagonizes BMP signaling to create a niche for adult neurogenesis, 2000, Neuron, vol. 28, pp. 713-726.
Concalves M, A concise peer into the background, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene repair, 2005, Gene Therapy, vol. 12, pp. 639-646.
High K, Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?, 2005, J. Thrombosis and Haemostasis, vol. 3, pp. 1682-1691.
Ellinwood et al., Gene therapy for lysosomal storage diseases: the lessons and promise of animal models, 2004, J. Gene Medicine, vol. 6, pp. 481-506.
Shekhar C., Gene therapy trial on hold, Jul. 31, 2007.
Mastakov et al., 2002, J. Virology, vol. 76, No. 16, pp. 8446-8454.
Lo et al., 1999, Human Gene Therapy, vol. 10, pp. 201-213.
Schubert et al., 2008, Molecular Therapy, vol. 16, No. 4, pp. 640-646.
Faulkner et al., 2005, J Neuroscience, vol. 24(9), pp. 2143-2155.
Trendenelburg et al., 2005, Glia, vol. 51, pp. 307-320.
Chen et al., “Transgenic Animals with Inducible, Targeted Gene Expression in Brain,”Molecular Pharmacology54:495-503 (1998).
Kalcheim et al., “Neurotrophin 3 is a Mitogen for Cultured Neural Crest Cells,”Proc. Natl. Acad. Sci. USA89:1661-1665 (1992).
Pixley et al., “Effects of Insulin-Like Growth Factor 1 on Olfactory Neurogenesis In Vivo and In Vitro,”Annals of the New York Academy of Sciences855:244-247 (1998).
Frade et al., “Insulin-Like Growth Factor-I Stimulates Neurogenesis in Chick Retina by Regulating Expression of the α6 Integrin Subunit,”Development122:2497-2506 (1996).
Gage et al., “Isolation, Characterization, and Use of Stem Cells From the CNS,”Annu. Rev. Neurosci. 18:159-192 (1995).
Gage et al., “Survival and Differentiation of Adult Neuronal Progenitor Cells Transplanted to the Adult Brain,”Proc. Natl. Acad. Sci. USA92:11879-11883 (1995).
Gao et al., “Neurotrophin-4/5 (NT-4/5) and Brain-Derived Neurotrophic Factor (BDNF) Act at Later Stages of Cerebellar Granule Cell Differentiation,”J. Neurosci. 15(4):2656-2667 (1995).
Memberg et al., “Proliferation, Differentiation, and Survival of Rat Sensory Neuron Precursors In Vitro Require Specific Trophic Factors,”Mol. Cell. Neurosci. 6:323-335 (1995).
Hoshimaru et al., “Differentiation of the Immortalized Adult Neuronal Progenitor Cell Line HC2S2 into Neurons by Regulatable Suppression of thev-mycOncogene,”Proc. Natl. Acad. Sci. USA93:1518-1523 (1996).
Ockel et al., “In Vivo Effects of Neurotrophin-3 During Sensory Neurogenesis,”Development122:301-307 (1996).
Gravel et al., “Adenoviral Gene Transfer of Ciliary Neurotrophic Factor and Brain-Derived Neurotrophic Factor Leads to Long Term Survival of Axotomized Motor Neurons,”Nature Medicine3:765-770 (1997).
Ribotta et al., “Prevention of Motoneuron Death by Adenovirus-Mediated Neurotrophic Factors,”J. Neurosci. Res.48:281-285 (1997).
DiPolo et al., “Prolonged Delivery of Brain-Derived Neurotrophic Factor by Adenovirus-Infected Müller Cells Temporarily Rescues Injured Retinal Ganglion Cells,”Proc. Nat'l. Acad. Sci. USA95:3978-3983 (1998).
Fariñas et al., “Characterization of Neurotrophin and Trk Receptor Functions in Developing Sensory Ganglia: Direct NT-3 Activation of TrkB Neurons In Vivo,”Neuron21:325-334 (1998).
Fukumitsu et al., “Simultaneous Expression of Brain-Derived Neurotrophic Factor and Neurotrophin-3 in Cajal-Retzius, Subplate and Ventricular Progenitor Cells During Early Development Stages of the Rat Cerebral Cortex,”Neurosci. 84(1):115-127(1998).
Kempermann et al., “New Nerve Cells for the Adult Brain. Adult Neurogenesis and Stem Cell Concept in Neurological Research,”Nervenarzt69(10):851-857 (1998) (English abstract).
Isenmann et al., “Excess Target-Derived Brain-Derived Neurotrophic Factor Preserves the Transient Uncrossed Retinal Projection to the Superior Colliculus,”Mol. Cell. Neurosci. 14:52-65 (1999).
Kukekov et al., “Multipotent Stem/Progenitor Cells with Similar Properties Arise from Two Neurogenic Regions of Adult Human Brain,”Experimental Neurology156:333-344 (1999).
Takahashi et al., “Retinoic Acid and Neurotrophins Collaborate to Regulate Neurogenesis in Adult-Derived Neural Stem Cell Cultures,”J. Neurobiology38:65-81 (1999).
Zaheer et al., “Enhanced Expression of Neurotrophic Factors by C6 Rat Glioma Cells After Transfection with Glia Maturation Factor,”Neuroscience Letters265:203-206 (1999).
Ahmed et al., “BDNF Enhances the Differentiation but Not the Survival of CNS Stem Cell-Derived Neuronal Precursors,”J. Neurosci. 15(8):5765-5778 (1995).
Alvarez-Buylla et al., “Neuronal Stem Cells in the Brain of Adult Vertebrates,”Stem Cells13:263-72 (1995).
Bajocchi et al., “Direct In Vivo Gene Transfer to Ependymal Cells in the Central Nervous System Using Recombinant Adenovirus Vectors,”Nature Genetics3:229-234 (1993).
Craig et al., “In Vivo Growth
Chmielnicki Eva
Economides Aris
Goldman Steven A.
Cornell Research Foundation Inc.
Crouch Deborah
Montanari David
Nixon & Peabody LLP
Regeneron Pharmaceuticals
LandOfFree
Enhancing neurotrophin-induced neurogenesis by endogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancing neurotrophin-induced neurogenesis by endogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing neurotrophin-induced neurogenesis by endogenous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4069431